17 research outputs found
Autologous transplantation of peripheral blood progenitor cells mobilized by chemotherapy with or without G-CSF (filgrastim) in resistant lymphoproliferative diseases: Enhanced hemopoietic recovery with filgrastim primed progenitors
Background and Methods. Bone marrow transplantation is increasingly used to overcome the bone marrow toxicity from myeloblative therapy. Peripheral blood progenitor cell transplantation (PBPCT) has been recognized as an alternative source of bone marrow for hemopoietic recovery after myeloblative therapy. In the steady state condition hemopoietic progenitors are scarce in peripheral blood; chemotherapy and growth factors are both able to increase PBPCs. Twenty-five patients affected by resistant lymphoproliferative diseases [4 multiple myeloma (MM), 19 non Hodgkin's lymphoma (NHL) and 2 Hodgkin's disease (HD)] were submitted to autologous peripheral blood progenitor cell transplantation (PBPCT). PBPCs were collected after chemotherapy (CT) alone (8 patients) or plus filgrastim (17 patients). Filgrastim was not administered after PBPCT in any case. Results and Conclusions. A statistically significant difference between the two groups was found for the following parameters: number of leukaphereses administered, amount of CFU-GM infused, time to hemopoietic recovery, amount of supportive care, number of days of antibiotic therapy, length of hospitalization. PBPCs primed with filgrastim CT appeared to be markedly superior to CT-recruited PBPCs in reducing the period of neutropenia and, surprisingly, of thrombocytopenia. Reduction in hematologic toxicity resulted in a decrease of transplantation-related toxicity and mortality, even in elderly and/or heavily pretreated patients
The hCOMET project: International database comparison of results with the comet assay in human biomonitoring. Baseline frequency of DNA damage and effect of main confounders
The alkaline comet assay, or single cell gel electrophoresis, is one of the most popular methods for assessing DNA damage in human population. One of the open issues concerning this assay is the identification of those factors that can explain the large inter-individual and inter-laboratory variation. International collaborative initiatives such as the hCOMET project a COST Action launched in 2016 represent a valuable tool to meet this challenge. The aims of hCOMET were to establish reference values for the level of DNA damage in humans, to investigate the effect of host factors, lifestyle and exposure to genotoxic agents, and to compare different sources of assay variability. A database of 19,320 subjects was generated, pooling data from 105 studies run by 44 laboratories in 26 countries between 1999 and 2019. A mixed random effect log-linear model, in parallel with a classic meta-analysis, was applied to take into account the extensive heterogeneity of data, due to descriptor, specimen and protocol variability. As a result of this analysis interquartile intervals of DNA strand breaks (which includes alkali-labile sites) were reported for tail intensity, tail length, and tail moment (comet assay descriptors). A small variation by age was reported in some datasets, suggesting higher DNA damage in oldest age-classes, while no effect could be shown for sex or smoking habit, although the lack of data on heavy smokers has still to be considered. Finally, highly significant differences in DNA damage were found for most exposures investigated in specific studies. In conclusion, these data, which confirm that DNA damage measured by the comet assay is an excellent biomarker of exposure in several conditions, may contribute to improving the quality of study design and to the standardization of results of the comet assay in human populations.(c) 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Odd and even partial waves of f \u3b7\u3c0 12\u3b7\u3c0 12 and \u3b7\u2032\u3c0 12\u3b7\u2032\u3c0 12 in \u3c0 12p\u2192\u3b7(\u2032)\u3c0 12p\u3c0 12p\u2192\u3b7(\u2032)\u3c0 12p at 191 GeV/c
Exclusive production of \u3b7\u3c0 12 and \u3b7 \u3c0 12 has been studied with a 191 GeV/c \u3c0 12 beam impinging
on a hydrogen target at COMPASS (CERN). Partial-wave analyses reveal different odd/even angular
momentum (L) characteristics in the inspected invariant mass range up to 3 GeV/c2. A striking similarity
between the two systems is observed for the L = 2, 4, 6 intensities (scaled by kinematical factors) and the
relative phases. The known resonances a2(1320) and a4(2040) are in line with this similarity. In contrast,
a strong enhancement of \u3b7 \u3c0 12 over \u3b7\u3c0 12 is found for the L = 1, 3, 5 waves, which carry non-q\uafq quantum
numbers. The L = 1 intensity peaks at 1.7 GeV/c2 in \u3b7 \u3c0 12 and at 1.4 GeV/c2 in \u3b7\u3c0 12, the corresponding
phase motions with respect to L =2 are different